Compliance, persistence, costs and quality of life in young patients treated with antipsychotic drugs: results from the COMETA study

BMC Psychiatry

Luciana Scalone⁸  Lorenzo G Mantovani¹  Maria G Giustra²  Fabiana L Lopes²  Miriam CJM Sturkenboom⁴  Patrizia Berto⁵  Elvezio Pirfo⁷  Ferrannini Luigi³  Claudio Mencacci⁶  Paolo A Cortesi⁸ 

[1] Dipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy;Medical Affairs, Janssen-Cilag SpA, Cologno Monzese, Milan, Italy;Departement of Mental Health, ASL 3 Genovese, Genoa, Italy;Department of Epidemiology & Biostatistics and Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands;PBE consulting, Verona, and School of Pharmacy, University of Padua, Padua, Italy;Mental Health Department, Fatebenefratelli Hospital, Milan, Italy;Mental Health Department G. Maccacaro, Turin, Italy;CHARTA Foundation, Milan, Italy

关键词: Quality of life;    Cost of illness;    Persistence;    Medication compliance;    Schizophrenia;   

Others  :  1124096
DOI  :  10.1186/1471-244X-13-98

 received in 2012-09-26, accepted in 2013-03-12,  发布年份 2013

【 摘 要 】

Background

Little data is available on the real-world socio-economic burden and outcomes in schizophrenia. This study aimed to assess persistence, compliance, costs and Health-Related Quality-of-Life (HRQoL) in young patients undergoing antipsychotic treatment according to clinical practice.

Methods

A naturalistic, longitudinal, multicentre cohort study was conducted: we involved 637 patients aged 18–40 years, with schizophrenia or schizophreniform disorder diagnosed ≤10 years before, enrolled in 86 Italian Mental Health Centres and followed-up for 1 year. Comparisons were conducted between naïve (i.e., patients visiting the centre for the first time and starting a new treatment regimen) and non naïve patients.

Results

At enrolment, 84% of patients were taking atypical drugs, 3.7% typical, 10% a combination of the two classes, and 2% were untreated. During follow-up, 23% of patients switched at least once to a different class of treatment, a combination or no treatment. The mean Drug-Attitude-Inventory score was 43.4, with 94.3% of the patients considered compliant by the clinicians. On average, medical costs at baseline were 390.93€/patient-month, mostly for drug treatment (29.5%), psychotherapy (29.2%), and hospitalizations (27.1%). Patients and caregivers lost 3.5 days/patient-month of productivity. During follow-up, attitude toward treatment remained fairly similar, medical costs were generally stable, while productivity, clinical statusand HRQoL significantly improved. While no significantly different overall direct costs trends were found between naïve and non naïve patients, naïve patients showed generally a significant mean higher improvement of clinical outcomes, HRQoL and indirect costs, compared to the others.

Conclusions

Our results suggest how tailoring the treatment strategy according to the complex and specific patient needs make it possible to achieve benefits and to allocate more efficiently resources. This study can also provide information on the most relevant items to be considered when conducting cost-effectiveness studies comparing specific alternatives for the treatment of target patients.

【 授权许可】

   
2013 Cortesi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]World Health Organization. http://www.who.int/mental_health/management/schizophrenia/en webcite
• [2]McGlashan TH: A selective review of recent North American long-term followup studies of schizophrenia. Schizophr Bull 1988, 14(4):515-542.
• [3]Ustün TB: The global burden of mental disorders. Am J Public Health 1999, 89(9):1315-1318.
• [4]Rössler W, Salize HJ, van Os J, Riecher-Rössler A: Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol 2005, 15(4):399-409.
• [5]Mueser K, McGurk S: Schizophrenia. Lancet 2004, 363(9426):2063-2072.
• [6]Knapp M, Mangalore R, Simon J: The global costs of schizophrenia. Schizophr Bull 2004, 30(2):279-293.
• [7]Stargardt T, Edel MA, Ebert A, Busse R, Juckel G, Gericke CA: Effectiveness and cost of atypical versus typical antipsychotic treatment in a nationwide cohort of patients with schizophrenia in Germany. J Clin Psychopharmacol 2012, 32(5):602-607.
• [8]Phanthunane P, Whiteford H, Vos T, Bertram M: Economic burden of schizophrenia: empirical analyses from a survey in Thailand. J Ment Health Policy Econ 2012, 15(1):25-32.
• [9]Sarlon E, Heider D, Millier A, Azorin JM, König HH, Hansen K, Angermeyer MC, Aballéa S, Toumi M: A prospective study of health care resource utilisation and selected costs of schizophrenia in France. BMC Health Serv Res 2012, 12:269-276. BioMed Central Full Text
• [10]Chang SM, Cho SJ, Jeon HJ, Hahm BJ, Lee HJ, Park JI, Cho MJ: Economic burden of schizophrenia in South Korea. J Korean Med Sci 2008, 23(2):167-175.
• [11]Terkelsen KG, Menikoff A: Measuring the costs of schizophrenia. Implications for the post-institutional era in the US. PharmacoEconomics 1995, 8(3):199-222.
• [12]NHS, The Information Centre for health and social care: Hospital Episode Statistics 2006–07. London: The NHS Information Centre; http://www.hesonline.nhs.uk webcite
• [13]Fitzgerald PB, Montgomery W, de Castella AR, Filia KM, Filia SL, Christova L, Jackson D, Kulkami J: Australian Schizophrenia Care and Assessment Programme: real-world schizophrenia: economics. Aust N Z J Psychiatry 2007, 41(10):819-829.
• [14]Oliva-Moreno J, López-Bastida J, Osuna-Guerrero R, Montejo-González AL, Duque-González B: The costs of schizophrenia in Spain. Eur J Health Econ 2006, 7(3):182-188.
• [15]Mangalore R, Knapp M: Cost of schizophrenia in England. J Ment Health Policy Econ 2007, 10(1):23-41.
• [16]Davies LM, Drummond MF: Economics and schizophrenia: the real cost. Br J Psychiatry Suppl 1994, 25:18-21.
• [17]Alonso J, Croudace T, Brown J, Gasquet I, Knapp MR, Suárez D, Novick D: Health-related quality of life (HRQL) and continuous antipsychotic treatment: 3-year results from the Schizophrenia Health Outcomes (SOHO) study. Value Health 2009, 12(4):536-543.
• [18]Kilian R, Angermeyer MC: The effects of antipsychotic treatment on quality of life of schizophrenic patients under naturalistic treatment conditions: an application of random effect regression models and propensity scores in an observational prospective trial. Qual Life Res 2005, 14(5):1275-1289.
• [19]Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. NEngl J Med 2005, 353(12):1209-1223.
• [20]Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Grobbee DE, EUFEST study group: Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008, 371(9618):1085-1097.
• [21]Tiihonen J, Wahlbeck K, Lönnqvist J, Klaukka T, Ioannidis JP, Volavka J, Haukka J: Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006, 333(7561):224.
• [22]Malla AK, Norman RM, Joober R: First-episode psychosis, early intervention, and outcome: what have we learned? Can J Psychiatry 2005, 50(14):881-891.
• [23]Perkins D, Lieberman J, Gu H, Tohen M, McEvoy J, Green A, Zipursky R, Strakowski S, Sharma T, Kahn R, Gur R, Tollefson G, HGDH Research Group: Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. Br J Psychiatry 2004, 185:18-24.
• [24]Strakowski SM, Johnson JL, Delbello MP, Hamer RM, Green AI, Tohen M, Lieberman JA, Glick I, Patel JK, HGDH Research Group: Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. Schizophr Res 2005, 78(2–3):161-169.
• [25]Amminger GP, Henry LP, Harrigan SM, Harris MG, Alvarez-Jimenez M, Herrman H, Jackson HJ, McGorry PD: Outcome in early-onset schizophrenia revisited: findings from the Early Psychosis Prevention and Intervention Centre long-term follow-up study. Schizophr Res 2011, 131(1–3):112-119.
• [26]Stafford MR, Jackson H, Mayo-Wilson E, Morrison AP, Kendall T: Early interventions to prevent psychosis: systematic review and meta-analysis. BMJ 2013, 346:f185.
• [27]Marshall M, Rathbone J: Early intervention for psychosis (review). Cochrane Database. Syst Rev 2011, 6:CD004718.
• [28]Gafoor R, Nitsch D, McCrone P, Craig TK, Garety PA, Power P, McGuire P: Effect of early intervention on 5-year outcome in non-affective psychosis. Br J Psychiatry 2010, 196(5):372-376.
• [29]Andreoli V, Cassano GB, Rossi R: Manuale diagnostico e statistico dei disturbi mentali (DSM-IV-TR), italian translation. Milano: MassonSpA; 2001.
• [30]World Medical Association (WMA) Declaration of Helsinki: Adopted by the 18th WMA General Assembly, held in Helsinki in June. 1964. http://www.wma.net/en/30publications/10policies/b3/index.html webcite
• [31]Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13(2):261-276.
• [32]Pancheri P, Brugnoli R, Carilli L, Marconi PL, Petrucci RM: Valutazione dimensionale della sintomatologia schizofrenica. Validazione della versione italiana della Scala per la valutazione dei Sintomi Positivi e Negativi (PANSS). Giorn Ital Psicopat 1995, 1:60-75.
• [33]Guy G: Clinical Global Impression. In ECDEU assessment manual for psychopharmacology, revised. Rockville (MD: National Institute of Mental Health; 1976.
• [34]Haro JM, Kamath SA, Ochoa S, Novick D, Rele K, Fargas A, Rodríguez MJ, Rele R, Orta J, Kharbeng A, Araya S, Gervin M, Alonso J, Mavreas V, Lavrentzou E, Liontos N, Gregor K, Jones PB, SOHO Study Group: The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl 2003, 416:16-23.
• [35]Endicott J, Spitzer RL, Fleiss JL, Cohen J: The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976, 33:766-771.
• [36]Rabin R, de Charro F: EQ-5D: a measure of health status from the EuroQolGroup. Ann Med 2001, 33(5):337-343.
• [37]Ware J Jr, Kosinski M, Keller SD: SF-36 Physical and Mental Health Summary Scales: A User’s Manual. Boston (MA): The Health Institute; 1994.
• [38]Pukrop R, Schlaak V, Moller-Leimkuhler AM, Albus M, Czernik A, Klosterkötter J, Möller HJ: Reliability and validity of Quality of Life assessed by the Short-Form 36 and the Modular System for Quality of Life in patients with schizophrenia and patients with depression. Psychiatry Res 2003, 119(1–2):63-79.
• [39]König HH, Roick C, Angermeyer MC: Validity of the EQ-5D in assessing and valuing health status in patients with schizophrenic, schizotypal or delusional disorders. Eur Psychiatry 2007, 22(3):177-187.
• [40]Prieto L, Novick D, Sacristán JA, Edgell ET, Alonso J, SOHO Study Group: A Rasch model analysis to test the cross-cultural validity of the EuroQoL-5D in the Schizophrenia Outpatient Health Outcomes Study. Acta Psychiatr Scand Suppl 2003, 416:24-29.
• [41]Prieto L, Sacristán JA, Hormaechea JA, Casado A, Badia X, Gómez JC: Psychometric validation of a generic health-related quality of life measure (EQ-5D) in a sample of schizophrenic patients. Curr Med Res Opin 2004, 20(6):827-835.
• [42]Badia X, Montserrat R, Herdman M, Kind P: A comparison of United Kingdom and Spanish General Population Time Trade-Off Values for EQ-5D Health States. Med Decis Making 2001, 21:7-16.
• [43]Ware JE Jr, Gandek B, Kosinski M, Aaronson NK, Apolone G, Brazier J, Bullinger M, Kaasa S, Leplège A, Prieto L, Sullivan M, Thunedborg K: The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 1998, 51(11):1167-1170.
• [44]Hogan TP, Awad AG, Eastwood R: A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983, 13:177-183.
• [45]Rossi A, Arduini L, de Cataldo S, Stratta P: Subjective response to neuroleptic medication: a validation study of the Italian version of the drug attitude inventory (DAI). Epidemiol Psichiatr Soc 2001, 10:107-114.
• [46]Reimbursement Price and Market. http://farmaco.agenziafarmaco.it/index.php webcite
• [47]Tariffari regionali delle prestazioni di assistenza ospedaliera. www.drg.it webcite
• [48]Nomenclatori Tariffari Regionali delle prestazioni specialistiche ambulatoriali. http://www.agenas.it/monitoraggio_costi_tariffe/monitoraggio_costi_tariffe_prestazioni.htm webcite
• [49]Bollettino Ufficiale Regione Lombardia, n.47, 20 November 2007, extraordinary supplement 1. http://www.infopoint.it/burlnew/home/home.aspx webcite
• [50]Drummond MF, Shulpher MJ, Torrance GW, O’Brein B, Stoddart GL: Methods for the economic evaluation of health care programmes. 3 (2005) edition. Oxford England: Oxford University Press; 1986.
• [51]Grover S, Avasthi A, Chakrabarti S, Bhansali A, Kulhara P: Cost of care of schizophrenia: a study of Indian out-patient attenders. Acta Psychiatr Scand 2005, 112(1):54-63.
• [52]The NICE guideline on core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. Updated edition. http://www.nice.org.uk/nicemedia/live/11786/43607/43607.pdf webcite
• [53]Serretti A, Mandelli L, Bajo E, Cevenini N, Papili P, Mori E, Bigelli M, Berardi D: The socio-economical burden of schizophrenia: a simulation of cost-offset of early intervention program in Italy. Eur Psychiatry 2009, 24(1):11-16.
• [54]Palazzolo J, Brousse G, Favre P, Llorca PM: The information of the schizophrenic patient: actuality. Encephale 2005, 31(2):227-234.
• [55]van Os J, Kapur S: Schizophrenia. Lancet 2009, 374(9690):635-645.
• [56]Bartels C, Wegrzyn M, Wiedl A, Ackermann V, Ehrenreich H: Practice effects in healthy adults: A longitudinal study on frequent repetitive cognitive testing. BMC Neurosci 2010, 11:118:1-12.
• [57]Guo X, Zhai J, Wei Q, Twamley EW, Jin H, Fang M, Hu M, Zhao J: Neurocognitive effects of first- and second-generation antipsychotic drugs in early-stage schizophrenia: a naturalistic 12-month follow-up study. Neurosci Lett 2011, 503(2):141-146.
• [58]Mazzaglia G, Mantovani LG, Sturkenboom MC, Filippi A, Trifirò G, Cricelli C, Brignoli O, Caputi AP: Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens 2005, 23(11):2093-2100.
• [59]Knapp M, Chisholm D, Leese M, Amaddeo F, Tansella M, Schene A, Thornicroft G, Vazquez-Barquero JL, Knudsen HC, Becker T: Comparing patterns and costs of schizophrenia care in five European countries: the EPSILON study. European Psychiatric Services: Inputs Linked to Outcome Domains and Needs. Acta Psychiatr Scand 2002, 105:42-54.